Julie Russell,  —

Recent Posts

• Phase 1 trial of CAR T-cell therapy will soon enroll AAV patients October 2, 2024
• CT scan damage may predict ANCA-associated vasculitis outcomes September 30, 2024
• Fasenra approval for EGPA in EU recommended by committee September 25, 2024
• Syndecan-1 levels may help ID AAV patients at risk of poor prognosis September 23, 2024
• FDA approves Fasenra for treating adults with rare AAV form EGPA September 19, 2024
• Rituximab may raise risks of adverse events in AAV: Study September 18, 2024
• Tavneos effective in AAV patients with lung bleeding: Real-world study September 16, 2024
• How I’ve been able to fulfill my dreams, even with ANCA vasculitis September 13, 2024
• Treating ANCA-associated vasculitis with rituximab tied to HGG risk September 11, 2024
• Rituximab treatment more effective than cyclophosphamide for GPA September 9, 2024